Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26351. Epub 2016 Dec 1.

PMID:
27905678
2.

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.

Irving JA, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV.

Blood. 2016 Aug 18;128(7):911-22. doi: 10.1182/blood-2016-03-704973. Epub 2016 May 26.

3.

The role of the RAS pathway in iAMP21-ALL.

Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, Towers W, Partington M, Elliott A, Minto L, Richardson S, Rahman T, Keavney B, Skinner R, Bown N, Haferlach T, Vandenberghe P, Haferlach C, Santibanez-Koref M, Moorman AV, Kohlmann A, Irving JA, Harrison CJ.

Leukemia. 2016 Sep;30(9):1824-31. doi: 10.1038/leu.2016.80. Epub 2016 Apr 22.

4.

Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition.

Nicholson L, Evans CA, Matheson E, Minto L, Keilty C, Sanichar M, Case M, Schwab C, Williamson D, Rainer J, Harrison CJ, Kofler R, Hall AG, Redfern CP, Whetton AD, Irving JA.

Br J Haematol. 2015 Nov;171(4):595-605. doi: 10.1111/bjh.13647. Epub 2015 Aug 27.

5.

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.

Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, Swidenbank I, Ponthan F, Kirschner-Schwabe R, Groeneveld-Krentz S, Hof J, Allan J, Harrison C, Vormoor J, von Stackelberg A, Eckert C.

Blood. 2014 Nov 27;124(23):3420-30. doi: 10.1182/blood-2014-04-531871. Epub 2014 Sep 24.

6.

Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia.

Nicholson L, Knight T, Matheson E, Minto L, Case M, Sanichar M, Bomken S, Vormoor J, Hall A, Irving J.

Genes Chromosomes Cancer. 2012 Mar;51(3):250-6. doi: 10.1002/gcc.20949. Epub 2011 Nov 10.

PMID:
22072526
7.

Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia.

Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, Jones L, Masic D, Minto L, Morrison H, Ryan S, Robinson H, Sinclair P, Moorman AV, Strefford JC, Harrison CJ.

Blood. 2011 Jun 23;117(25):6848-55. doi: 10.1182/blood-2011-01-329961. Epub 2011 Apr 28.

PMID:
21527530
8.

Mismatch repair and the downstream target genes, PAX5 and Ikaros, in childhood acute lymphoblastic leukemia.

Best A, Matheson E, Minto L, Hall AG, Irving JA.

Leuk Res. 2010 Aug;34(8):1098-102. doi: 10.1016/j.leukres.2010.02.017. Epub 2010 Mar 15.

PMID:
20233627
9.

Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia.

Wilson K, Case M, Minto L, Bailey S, Bown N, Jesson J, Lawson S, Vormoor J, Irving J.

Haematologica. 2010 Apr;95(4):679-83. doi: 10.3324/haematol.2009.011726. Epub 2009 Nov 30.

10.

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.

Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, Guttery DS, Haferlach C, Harder L, Heidenreich O, Irving J, Kearney L, Nguyen-Khac F, Machado L, Minto L, Majid A, Moorman AV, Morrison H, Rand V, Strefford JC, Schwab C, Tönnies H, Dyer MJ, Siebert R, Harrison CJ.

Blood. 2009 Sep 24;114(13):2688-98. doi: 10.1182/blood-2009-03-208397. Epub 2009 Jul 29.

PMID:
19641190
11.

Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.

Irving J, Jesson J, Virgo P, Case M, Minto L, Eyre L, Noel N, Johansson U, Macey M, Knotts L, Helliwell M, Davies P, Whitby L, Barnett D, Hancock J, Goulden N, Lawson S; UKALL Flow MRD Group; UK MRD steering Group.

Haematologica. 2009 Jun;94(6):870-4. doi: 10.3324/haematol.2008.000414. Epub 2009 Apr 18.

12.

Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer.

An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Hall AG, Harrison CJ, Irving JA, Strefford JC.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17050-4. doi: 10.1073/pnas.0803494105. Epub 2008 Oct 28.

13.

A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups.

Sulong S, Moorman AV, Irving JA, Strefford JC, Konn ZJ, Case MC, Minto L, Barber KE, Parker H, Wright SL, Stewart AR, Bailey S, Bown NP, Hall AG, Harrison CJ.

Blood. 2009 Jan 1;113(1):100-7. doi: 10.1182/blood-2008-07-166801. Epub 2008 Oct 6.

PMID:
18838613
14.

Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.

Case M, Matheson E, Minto L, Hassan R, Harrison CJ, Bown N, Bailey S, Vormoor J, Hall AG, Irving JA.

Cancer Res. 2008 Aug 15;68(16):6803-9. doi: 10.1158/0008-5472.CAN-08-0101.

15.

Genomic analysis of different clonal evolution in a twin pair with t(12;21) positive acute lymphoblastic leukemia sharing the same prenatal clone.

Bungaro S, Irving J, Tussiwand R, Mura R, Minto L, Molteni C, Citterio M, Hall A, Biondi A, Cazzaniga G.

Leukemia. 2008 Jan;22(1):208-11. Epub 2007 Oct 11. No abstract available.

PMID:
17914410
16.

Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor.

Schmidt S, Irving JA, Minto L, Matheson E, Nicholson L, Ploner A, Parson W, Kofler A, Amort M, Erdel M, Hall A, Kofler R.

FASEB J. 2006 Dec;20(14):2600-2. Epub 2006 Oct 31.

PMID:
17077285
17.

Sweet problems: insect traits defining the limits to dietary sugar utilisation by the pea aphid, Acyrthosiphon pisum.

Douglas AE, Price DR, Minto LB, Jones E, Pescod KV, François CL, Pritchard J, Boonham N.

J Exp Biol. 2006 Apr;209(Pt 8):1395-403.

19.

The significance of gut sucrase activity for osmoregulation in the pea aphid, Acyrthosiphon pisum.

Karley AJ, Ashford DA, Minto LM, Pritchard J, Douglas AE.

J Insect Physiol. 2005 Dec;51(12):1313-9. Epub 2005 Sep 15.

PMID:
16169004
20.

Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.

Meier M, den Boer ML, Hall AG, Irving JA, Passier M, Minto L, van Wering ER, Janka-Schaub GE, Pieters R.

Leukemia. 2005 Nov;19(11):1887-95.

PMID:
16167060
21.

The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.

Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J.

Br J Haematol. 2005 Sep;130(6):964-5. No abstract available.

PMID:
16156866
22.

Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.

Irving JA, O'Brien S, Lennard AL, Minto L, Lin F, Hall AG.

Clin Chem. 2004 Jul;50(7):1233-7. No abstract available.

23.

Antibodies against 9-O-acetylated sialoglycans: a potent marker to monitor clinical status in childhood acute lymphoblastic leukemia.

Pal S, Bandyopadhyay S, Chatterjee M, Bhattacharya DK, Minto L, Hall AG, Mandal C.

Clin Biochem. 2004 May;37(5):395-403.

PMID:
15087256
24.

An integrated care pathway for the last two days of life: Wales-wide benchmarking in palliative care.

Fowell A, Finlay I, Johnstone R, Minto L.

Int J Palliat Nurs. 2002 Dec;8(12):566-73.

PMID:
12560798
25.

The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs.

Coulthard SA, Hogarth LA, Little M, Matheson EC, Redfern CP, Minto L, Hall AG.

Mol Pharmacol. 2002 Jul;62(1):102-9.

PMID:
12065760
26.

Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents.

Bergoglio V, Canitrot Y, Hogarth L, Minto L, Howell SB, Cazaux C, Hoffmann JS.

Oncogene. 2001 Sep 27;20(43):6181-7.

27.

The impact of host plant on the abundance and function of symbiotic bacteria in an aphid.

Wilkinson TL, Adams D, Minto LB, Douglas AE.

J Exp Biol. 2001 Sep;204(Pt 17):3027-38.

28.

The use of denaturing high-pressure liquid chromatography for the detection of mutations in thiopurine methyltransferase.

Hall AG, Hamilton P, Minto L, Coulthard SA.

J Biochem Biophys Methods. 2001 Jan 30;47(1-2):65-71.

PMID:
11179762
29.

Quantifying nutrient production by the microbial symbionts in an aphid.

Douglas AE, Minto LB, Wilkinson TL.

J Exp Biol. 2001 Jan;204(Pt 2):349-58.

30.

A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations.

Coulthard SA, Rabello C, Robson J, Howell C, Minto L, Middleton PG, Gandhi MK, Jackson G, McLelland J, O'Brien H, Smith S, Reid MM, Pearson AD, Hall AG.

Br J Haematol. 2000 Sep;110(3):599-604.

PMID:
10997970

Supplemental Content

Support Center